Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 22 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 10316105

    Anti-TIE2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted
  2. US 10306874

    Non-human animals having a humanized lymphocyte-activation gene 3

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 4, 2019 · Expires May 30, 2039

    granted
  3. US 10285388

    Non-human animals having a disruption in a C9ORF72 locus

    REGENERON PHARMACEUTICALS, INC. · Granted May 14, 2019 · Expires May 9, 2039

    granted
  4. US 10278374

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted May 7, 2019 · Expires May 2, 2039

    granted
  5. US 10266588

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted
  6. US 10266582

    GPR156 variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted
  7. US 10259870

    Anti-ANGPTL8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted
  8. US 10261094

    Competitive ligand binding assay for detecting neutralizing antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted
  9. US 10253102

    Antigen-binding proteins that activate the leptin receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 9, 2019 · Expires Apr 4, 2039

    granted
  10. US 10251938

    Angiopoietin-based interventions for treating cerebral malaria

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 9, 2019 · Expires Apr 4, 2039

    granted
  11. US 10246509

    Restricted immunoglobulin heavy chain mice

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted
  12. US 10233250

    Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted
  13. US 10212923

    Humanized dipeptidyl-peptidase IV (DPP4) animals

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 26, 2019 · Expires Feb 21, 2039

    granted
  14. US 10206379

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 19, 2019 · Expires Feb 14, 2039

    granted
  15. US 10196613

    Stem cells for modeling type 2 diabetes

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  16. US 10189901

    Methods for improving cardiac function by administering an antibody that activates APLNR

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 29, 2019 · Expires Jan 24, 2039

    granted
  17. US 10179819

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 15, 2019 · Expires Jan 10, 2039

    granted
  18. US 10162933

    High resolution allele identification

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted
  19. US 10155811

    APLNR modulators and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 18, 2018 · Expires Dec 13, 2038

    granted
  20. US 10137193

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted
  21. US 10130681

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted
  22. US 10123518

    Genetically modified non-human animals and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  23. US 10125188

    Human antibodies to respiratory syncytial virus F protein and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  24. US 10111953

    Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 30, 2018 · Expires Oct 25, 2038

    granted